Questions/Treatment Planning
๐Ÿ“‹

Treatment Planning

Evidence-based treatment algorithms, level of care decisions, treatment resistance, and collaborative care models.

140 questions ยท Exam weight: ~15%
What the ANCC exam testsโ–ถ

Treatment Planning accounts for approximately 15% of the ANCC exam. This domain tests your ability to develop comprehensive, evidence-based treatment plans that integrate pharmacotherapy, psychotherapy, and level-of-care decisions. The exam expects you to think beyond prescribing, treatment planning includes safety planning, measurement-based care, and coordination with other providers.

Key areas include stepped care models (matching treatment intensity to symptom severity), augmentation vs. switching strategies for partial responders, and integrated treatment for dual-diagnosis patients. You need to know first-line and second-line treatments for major disorders, when to escalate care (outpatient to PHP to inpatient), and the criteria that guide these transitions.

The exam also tests collaborative care models, shared decision-making principles, and relapse prevention planning. Expect questions on specific protocols: the Stanley-Brown Safety Planning Intervention, measurement-based care using PHQ-9/GAD-7 thresholds to guide treatment adjustments, and evidence-based indications for ECT, TMS, and other somatic therapies.

Common mistakes to avoidโ–ถ
  • โœ•Jumping to augmentation before optimizing the current medication. The exam tests whether you know to ensure adequate dose and duration (typically 4-6 weeks at therapeutic dose) before adding a second agent or switching.
  • โœ•Not matching treatment intensity to acuity level. A patient with passive suicidal ideation without a plan may be safely managed outpatient with a safety plan, while active ideation with intent and means requires inpatient stabilization. The exam tests nuanced risk stratification, not reflexive hospitalization.
  • โœ•Treating comorbid conditions sequentially when integrated treatment is indicated. For co-occurring PTSD and substance use disorder, evidence supports integrated treatment (addressing both simultaneously) rather than the outdated "treat the addiction first" approach.
  • โœ•Forgetting to include psychotherapy in treatment plans. The exam expects pharmacotherapy combined with evidence-based psychotherapy for most conditions. CBT for anxiety and depression, DBT for borderline personality, PE/CPT for PTSD. Medication alone is rarely the complete answer.
  • โœ•Ignoring patient preferences in treatment decisions. Shared decision-making is a tested concept, the exam presents scenarios where the clinically "best" option isn't what the patient wants, and you need to navigate that appropriately.

Practice Treatment Planning

Build a custom quiz focused on treatment planning, pick your difficulty, set the length, and track your score across all ANCC exam domains. Free account required.

Build a Quiz

All 140 questions

1.
First-Line SSRI Selection for MDD
beginnerMDDSSRIpharmacotherapy
โ†’
2.
Augmentation Strategies for Treatment-Resistant Depression
intermediatetreatment-resistant depressionaugmentationaripiprazole
โ†’
3.
First-Line Pharmacotherapy for Acute Mania
intermediatebipolar disorderacute manialithium
โ†’
4.
Medication Selection for Comorbid Anxiety and Depression
beginnercomorbidityGADMDD
โ†’
5.
Level of Care Criteria: Inpatient vs. Outpatient
beginnersuicide risk assessmentlevel of careinpatient
โ†’
6.
Collaborative Care Model Roles
intermediatecollaborative careCoCMintegrated care
โ†’
7.
Clozapine Indication in Treatment-Resistant Schizophrenia
advancedclozapinetreatment-resistant schizophreniaANC monitoring
โ†’
8.
Stepped Care Model for Depression
beginnerstepped caremild depressionPHQ-9
โ†’
9.
Augment vs. Switch: Antidepressant Partial Response
intermediateaugmentationswitchingpartial response
โ†’
10.
Collaborative Care: Treatment-to-Target Adjustment
intermediatecollaborative caretreat-to-targetcaseload review
โ†’
11.
Treatment Planning for Depression with Alcohol Use Disorder
intermediatedual diagnosisalcohol use disorderMDD
โ†’
12.
Relapse Prevention Planning for Bipolar Disorder
intermediatebipolar disorderrelapse preventionlithium
โ†’
13.
Stanley-Brown Safety Planning Intervention
beginnersafety planningStanley-Brownsuicide prevention
โ†’
14.
Motivational Interviewing in Treatment Planning
intermediatemotivational interviewingOARSambivalence
โ†’
15.
Cultural Considerations in Medication Selection
intermediatecultural considerationspharmacogenomicsCYP2C19
โ†’
16.
Shared Decision-Making with Treatment-Resistant Depression
advancedshared decision-makingtreatment-resistant depressionpatient autonomy
โ†’
17.
Tapering Plan for Long-Term Benzodiazepine Use
advancedbenzodiazepine taperingclonazepamdiazepam
โ†’
18.
ECT Indications and Treatment Planning
advancedECTpsychotic depressiontreatment-resistant depression
โ†’
19.
Measurement-Based Care: Evidence for Implementation Over Clinical Judgment Alone
intermediatemeasurement-based carequality improvementPHQ-9
โ†’
20.
Treatment of Comorbid PTSD and Substance Use Disorder
intermediatePTSDsubstance use disorderintegrated treatment
โ†’
21.
Motivational Interviewing and Stages of Change Framework
intermediatemotivational interviewingstages of changecontemplation
โ†’
22.
SSRI Discontinuation Syndrome and Tapering Principles
intermediateSSRI discontinuation syndromeparoxetinetapering
โ†’
23.
Augmentation Strategies for Treatment-Resistant OCD
advancedtreatment-resistant OCDaugmentationrisperidone
โ†’
24.
Clozapine Initiation Criteria and Monitoring Requirements
advancedclozapineANC monitoring protocolANC monitoring
โ†’
25.
Light Therapy for Seasonal Affective Disorder
beginnerseasonal affective disorderlight therapycircadian rhythm
โ†’
26.
Eating Disorder Level of Care: Medical Instability Criteria
intermediateanorexia nervosalevel of caremedical stabilization
โ†’
27.
Integrating Peer Support Specialists into Treatment Planning
beginnerpeer supportrecovery modelserious mental illness
โ†’
28.
Opioid Use Disorder: Methadone vs. Buprenorphine Treatment Selection
intermediateopioid use disordermethadonebuprenorphine
โ†’
29.
Integrated vs. Sequential Treatment for Dual Diagnosis
intermediatedual diagnosisintegrated treatmentco-occurring disorders
โ†’
30.
Suicide Risk Stratification and Disposition Decision-Making
advancedsuicide risk stratificationdispositioninvoluntary admission
โ†’
31.
Medication Management During an ECT Course
advancedECTlithiumbenzodiazepine
โ†’
32.
Tobacco Cessation Pharmacotherapy Selection
beginnertobacco cessationvareniclinesmoking
โ†’
33.
Step-Down from Inpatient to Partial Hospitalization: Transition Planning
intermediatepartial hospitalizationstep-down caredischarge planning
โ†’
34.
Lithium Augmentation in Treatment-Resistant Depression
intermediatetreatment-resistant depressionlithium augmentationTRD
โ†’
35.
Stepped Care Model for Generalized Anxiety Disorder
beginnerstepped caregeneralized anxiety disorderGAD-7
โ†’
36.
Collaborative Care Model Integration for Depression
intermediatecollaborative care modelpsychiatric consultationmeasurement-based care
โ†’
37.
Using PHQ-9 and GAD-7 Thresholds for Treatment Decisions
beginnerPHQ-9GAD-7measurement-based care
โ†’
38.
Relapse Prevention Planning for Alcohol Use Disorder
intermediaterelapse preventionalcohol use disordersubstance use disorders
โ†’
39.
ECT Indications for Catatonic Depression
advancedECTelectroconvulsive therapycatatonia
โ†’
40.
Treatment Planning for Comorbid PTSD and Substance Use
advancedPTSDsubstance use disordercomorbid treatment
โ†’
41.
Shared Decision-Making in Antipsychotic Selection
intermediateshared decision-makingantipsychoticshyperprolactinemia
โ†’
42.
Pre-ECT Assessment โ€” Cardiac and Anesthesia Risk
advancedECTtreatment-resistant depressionpre-procedure assessment
โ†’
43.
Augmentation Rationale in Treatment-Resistant Depression
intermediatetreatment-resistant depressionaugmentationSTAR*D
โ†’
44.
Treatment Selection for Bipolar Depression
intermediatebipolar disorderbipolar depressionmood stabilizer
โ†’
45.
PTSD First-Line vs Second-Line Treatment Rationale
intermediatePTSDtrauma-focused therapySSRI
โ†’
46.
OCD Treatment Algorithm: ERP and Medication Integration
hardOCDERPexposure and response prevention
โ†’
47.
Shared Decision-Making in Antipsychotic Selection
intermediateshared decision-makingantipsychoticmetabolic effects
โ†’
48.
Comorbid Anxiety and Substance Use Treatment Prioritization
hardcomorbidityanxietysubstance use disorder
โ†’
49.
Discontinuation Syndrome Prevention Strategies
intermediatediscontinuation syndromeSSRItapering
โ†’
50.
Switching Antidepressant Classes and Washout Period Considerations
hardMAOIserotonin syndromewashout period
โ†’
51.
Metabolic Monitoring Rationale for Atypical Antipsychotics
intermediatemetabolic monitoringatypical antipsychoticschizophrenia
โ†’
52.
Treatment Planning for Comorbid ADHD and Mood Disorder
hardADHDmajor depressive disordercomorbidity
โ†’
53.
Psychotherapy Selection Matching: CBT vs DBT vs EMDR
hardpsychotherapy selectionDBTEMDR
โ†’
54.
Relapse Prevention Planning for Major Depressive Disorder
intermediaterelapse preventionmajor depressive disordermaintenance treatment
โ†’
55.
Evaluating SSRI Partial Response at 6 Weeks
intermediateSSRIpartial responsedose optimization
โ†’
56.
Monitoring Lithium Levels and Toxicity Recognition
hardlithiumtherapeutic drug monitoringtoxicity
โ†’
57.
Assessing Antipsychotic Response Using Rating Scales
hardschizophreniaBPRSantipsychotic response
โ†’
58.
Evaluating CBT Outcomes for Anxiety Using Standardized Measures
intermediateCBTGAD-7generalized anxiety disorder
โ†’
59.
Recognizing SSRI-Induced Apathy vs Residual Depression
hardSSRIemotional bluntingapathy syndrome
โ†’
60.
Monitoring Metabolic Syndrome with Atypical Antipsychotics
intermediatemetabolic syndromeolanzapineatypical antipsychotics
โ†’
61.
Evaluating Stimulant Response in Adult ADHD
intermediateADHDstimulantsASRS
โ†’
62.
Assessing Treatment Adherence Barriers
hardadherencelamotriginebipolar disorder
โ†’
63.
Recognizing Tardive Dyskinesia Early with AIMS Assessment
intermediatetardive dyskinesiaAIMShaloperidol
โ†’
64.
Evaluating PTSD Treatment Response with PCL-5
hardPTSDPCL-5prolonged exposure therapy
โ†’
65.
Monitoring for Suicidality During Early Antidepressant Treatment
hardsuicidalityFDA black box warningSSRI
โ†’
66.
Evaluating Psychotherapy Progress and Modality Adjustment
hardpsychotherapyIPTCBT
โ†’
67.
First-Line Treatment Planning for Pediatric ADHD
intermediateADHDpediatricstimulant
โ†’
68.
Antidepressant Selection with Hepatic Comorbidity
hardantidepressanthepatic impairmentSSRI
โ†’
69.
Crisis Intervention and Safety Planning
intermediatesafety planningsuicidal ideationStanley-Brown
โ†’
70.
Integrating Pharmacotherapy with Psychotherapy for PTSD
intermediatePTSDcombined treatmentpsychotherapy
โ†’
71.
Insomnia Treatment in Comorbid Depression
hardinsomniaCBT-Icomorbid insomnia
โ†’
72.
Geriatric Antipsychotic Risk-Benefit Planning
hardgeriatricantipsychoticdementia
โ†’
73.
Bipolar Maintenance Medication Planning
intermediatebipolar disorderlithiummaintenance treatment
โ†’
74.
Collaborative Treatment Planning with Primary Care
intermediatecollaborative careprimary care integrationchronic kidney disease
โ†’
75.
Stages of Change in Substance Use Treatment Planning
intermediatesubstance use disorderopioid use disorderstages of change
โ†’
76.
ECT Indications and Treatment Planning
hardECTpsychotic depressiontreatment-resistant
โ†’
77.
Planning for Medication Non-Adherence
intermediateschizophreniamedication adherencelong-acting injectable
โ†’
78.
Treatment Planning for Comorbid Chronic Pain and Depression
hardchronic paindepressionSNRI
โ†’
79.
Measuring Functional Improvement vs Symptom Reduction
intermediatefunctional impairmentPHQ-9Sheehan Disability Scale
โ†’
80.
Evaluating DBT Outcomes in Borderline Personality Disorder
intermediateDBTborderline personality disorderself-harm
โ†’
81.
Assessing Treatment Response in Pediatric Anxiety
intermediatepediatric anxietySCAREDmulti-informant assessment
โ†’
82.
Assessing Quality of Life in Chronic Mental Illness
hardquality of lifeschizophreniarecovery-oriented care
โ†’
83.
Clozapine Initiation Criteria and Monitoring
hardclozapinetreatment-resistant schizophreniaREMS
โ†’
84.
Treatment Planning for Refractory OCD
hardOCDtreatment-resistantantipsychotic augmentation
โ†’
85.
Esketamine Treatment Protocol Planning
hardesketamineSpravatotreatment-resistant depression
โ†’
86.
Geriatric Depression Augmentation Strategy
hardgeriatric depressionaugmentationaripiprazole
โ†’
87.
Adolescent Substance Use Treatment Planning
intermediateadolescentsubstance usecannabis
โ†’
88.
Pharmacogenomic-Guided Treatment Planning
hardpharmacogenomicsCYP2D6CYP2C19
โ†’
89.
Comorbid PTSD and SUD Treatment Planning
hardPTSDsubstance use disorderalcohol use disorder
โ†’
90.
Long-Acting Injectable Antipsychotic Planning
hardlong-acting injectablerisperidonepaliperidone
โ†’
91.
TMS Neurostimulation Indications Planning
intermediateTMStranscranial magnetic stimulationtreatment-resistant depression
โ†’
92.
Treatment-Resistant Bipolar Depression Planning
hardbipolar depressiontreatment-resistantquetiapine
โ†’
93.
Collaborative Care Model Implementation
intermediatecollaborative careIMPACT trialprimary care integration
โ†’
94.
Perinatal Depression Treatment Planning
hardperinatal depressionpregnancysertraline
โ†’
95.
Measuring Motivational Interviewing Outcomes for SUD
hardmotivational interviewingalcohol use disorderAUDIT
โ†’
96.
Evaluating EMDR Response for Trauma
hardEMDRPTSDPCL-5
โ†’
97.
Evaluating IPT Response for Depression
intermediateinterpersonal therapyIPTdepression
โ†’
98.
Concurrent Buprenorphine and Antidepressant Therapy Planning
hardbuprenorphineantidepressantopioid use disorder
โ†’
99.
Treatment Planning for Catatonia with Lorazepam Challenge
hardcatatonialorazepam challengebenzodiazepines
โ†’
100.
Antidepressant Selection in a Patient with Cardiac Disease
hardcardiacpost-MI depressionsertraline
โ†’
101.
Treatment Planning for Comorbid Epilepsy and Depression
hardepilepsydepressionlamotrigine
โ†’
102.
Treatment Planning for Late-Life Psychosis
hardlate-life psychosisParkinsonismquetiapine
โ†’
103.
Prevention of Serotonin Discontinuation Syndrome
harddiscontinuation syndromeparoxetinetaper strategy
โ†’
104.
Antipsychotic Selection in a Patient with Diabetes
intermediateschizophreniadiabetesmetabolic syndrome
โ†’
105.
Treatment Planning for Pediatric OCD
hardpediatric OCDfluvoxamineCBT
โ†’
106.
Treatment Planning for Treatment-Resistant Anxiety
hardtreatment-resistant anxietyGADbuspirone
โ†’
107.
Planning Cross-Taper Between Antipsychotics
hardcross-taperantipsychotic switchingolanzapine
โ†’
108.
Treatment Planning for Substance-Induced Psychosis
intermediatesubstance-induced psychosismethamphetaminebenzodiazepines
โ†’
109.
Treatment Planning for Comorbid Autism and Aggression
intermediateautismaggressionrisperidone
โ†’
110.
Medication Management Planning for First-Episode Psychosis
hardfirst-episode psychosisantipsychoticssecond-generation antipsychotics
โ†’
111.
Treatment Planning for Comorbid Generalized Anxiety Disorder and Insomnia
hardgeneralized anxiety disorderinsomniacomorbidity
โ†’
112.
Planning for Acute Agitation in Emergency Psychiatric Settings
hardacute agitationemergency psychiatryintramuscular antipsychotics
โ†’
113.
Treatment Planning for Treatment-Resistant Schizophrenia
hardtreatment-resistant schizophreniaclozapineREMS
โ†’
114.
Planning Stepped-Care Model for Depression
hardstepped caredepressiontreatment planning
โ†’
115.
Treatment Planning for Anorexia Nervosa with Comorbid Depression
hardanorexia nervosadepressioneating disorders
โ†’
116.
Planning Medication Management During Breastfeeding
hardpostpartum depressionbreastfeedinglactation
โ†’
117.
Treatment Planning for Acute Mania
hardbipolar disorderacute manialamotrigine
โ†’
118.
Planning Treatment for Comorbid Fibromyalgia and Depression
hardfibromyalgiadepressionduloxetine
โ†’
119.
Treatment Planning for Adolescent Self-Harm
hardadolescentself-harmNSSI
โ†’
120.
Planning Medication Management for Chronic PTSD
hardPTSDsertralineprazosin
โ†’
121.
Treatment Planning for Tardive Dyskinesia Management
hardtardive dyskinesiaVMAT2 inhibitorvalbenazine
โ†’
122.
Evaluating Response to CBT Augmentation for Treatment-Resistant OCD
hardOCDexposure and response preventionY-BOCS
โ†’
123.
Evaluating Response to Integrated Dual-Diagnosis Treatment
harddual diagnosisbipolar II disorderalcohol use disorder
โ†’
124.
Evaluating Treatment Response in Panic Disorder
hardpanic disorderagoraphobiaPDSS
โ†’
125.
Evaluating Treatment Response in Insomnia Using Sleep Diary
hardinsomniaCBT-Isleep diary
โ†’
126.
Evaluating Family Therapy Outcomes in Adolescent Depression
hardadolescent depressionattachment-based family therapyfamily therapy
โ†’
127.
Planning Medication Management for Serotonin Syndrome Prevention
hardserotonin syndromedrug interactionsSNRI
โ†’
128.
Treatment Planning for Social Phobia with Comorbid Avoidant Personality Disorder
hardsocial anxiety disorderavoidant personality disordercomorbidity
โ†’
129.
Planning Treatment for Grief-Related Depression
hardprolonged grief disordermajor depressive disordercomplicated grief treatment
โ†’
130.
Treatment Planning for ADHD in College Students
hardADHDstimulantscollege students
โ†’
131.
Planning Integrated Primary Care and Behavioral Health
hardcollaborative careintegrated careFQHC
โ†’
132.
Treatment Planning for Dissociative Identity Disorder
harddissociative identity disorderphase-oriented treatmenttrauma
โ†’
133.
Planning Withdrawal Management for Polysubstance Use
hardpolysubstance withdrawalalcohol withdrawalbenzodiazepine withdrawal
โ†’
134.
Treatment Planning for Chronic Suicidality in Borderline Personality Disorder
hardborderline personality disorderchronic suicidalityDBT
โ†’
135.
Planning Pharmacotherapy for Postpartum Psychosis
hardpostpartum psychosislithiumbipolar disorder
โ†’
136.
Treatment Planning for Conversion Disorder
hardconversion disorderfunctional neurological disorderpsychoeducation
โ†’
137.
Planning Treatment for Body Dysmorphic Disorder
hardbody dysmorphic disorderSSRICBT
โ†’
138.
Treatment Planning for Co-Occurring Chronic Illness and Depression
harddiabetesneuropathic painduloxetine
โ†’
139.
Planning Discharge and Transition of Care
harddischarge planningtransition of carelong-acting injectable
โ†’
140.
Planning Trauma-Focused Treatment Sequencing
hardcomplex PTSDtrauma treatmentphased model
โ†’

Related case studies

Practice treatment planning concepts with interactive clinical scenarios that test diagnostic reasoning and clinical decision-making.

๐ŸŒŠ Mood Disorders (13)๐Ÿงช Substance Use & Comorbidity (5)๐Ÿ› ๏ธ Clinical Skills (23)

Related domains

๐Ÿ’Š Psychopharmacology๐Ÿ” Diagnosis & Assessment๐Ÿ—ฃ๏ธ Psychotherapy
โ† All domains